Market Price

49.79 

0.07 0.1%

as of Jan 23 '19

52 Week Range:

44.30 70.05


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; Mirati Therapeutics, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 5.35
6.18
8.69
9.25
9.84
8.36
8.97
9.16
9.08
9.38
9.10
growth rate 15.5% 40.6% 6.4% 6.4% -15.0% 7.3% 2.1% -0.9% 3.3% -3.0%
Earnings BIT 3,530.00
5,470.00
5,600.00
6,070.00
6,980.00
2,340.00
2,890.00
3,468.00
3,867.00
5,186.00
5,350.00
growth rate 55.0% 2.4% 8.4% 15.0% -66.5% 23.5% 20.0% 11.5% 34.1% 3.2%
Avg.PE 26.81
14.62
15.48
14.79
16.31
28.09
34.48
50.43
68.60
21.30
102.79
growth rate -45.5% 5.9% -4.5% 10.3% 72.2% 22.8% 46.3% 36.0% -69.0% 382.6%
ROA 8.37
18.83
35.05
9.99
11.58
5.69
6.88
5.54
4.78
13.62
2.99
growth rate 125.0% 86.1% -71.5% 15.9% -50.9% 20.9% -19.5% -13.7% 184.9% -78.1%
ROE 21.07
46.02
78.36
20.30
23.42
13.25
17.81
13.36
10.75
29.28
7.21
growth rate 118.4% 70.3% -74.1% 15.4% -43.4% 34.4% -25.0% -19.5% 172.4% -75.4%
ROIC 13.46
29.30
53.33
14.89
17.60
10.15
12.31
9.43
7.83
20.91
4.90
growth rate 117.7% 82.0% -72.1% 18.2% -42.3% 21.3% -23.4% -17.0% 167.1% -76.6%
Cur. Ratio 1.20
2.20
2.21
1.97
1.97
1.15
1.52
1.73
1.30
1.55
1.55
growth rate 83.3% 0.5% -10.9% 0.0% -41.6% 32.2% 13.8% -24.9% 19.2% 0.0%
Quick Ratio 0.75
1.78
1.85
1.60
1.60
0.71
0.63
1.28
1.07
1.35
1.37
growth rate 137.3% 3.9% -13.5% 0.0% -55.6% -11.3% 103.2% -16.4% 26.2% 1.5%
Leverage 2.48
2.41
2.09
1.98
2.07
2.63
2.55
2.27
2.23
2.08
2.86
growth rate -2.8% -13.3% -5.3% 4.6% 27.1% -3.0% -11.0% -1.8% -6.7% 37.5%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 0.00
0.00
0.00
4,943.00
4,680.00
5,061.00
3,212.00
4,117.00
4,916.00
5,609.00
growth rate -5.3% 8.1% -36.5% 28.2% 19.4% 14.1%
Acct.Payable 7,328.00
6,628.00
6,394.00
2,487.00
1,565.00
1,664.00
2,248.00
growth rate -9.6% -3.5% -61.1% -37.1% 6.3% 35.1%
Cur.Assets 14,697.00
13,958.00
13,273.00
15,318.00
9,521.00
18,916.00
14,608.00
10,415.00
13,704.00
14,854.00
growth rate -5.0% -4.9% 15.4% -37.8% 98.7% -22.8% -28.7% 31.6% 8.4%
Total Assets 29,486.00
31,008.00
31,076.00
32,970.00
35,897.00
38,592.00
33,749.00
31,748.00
33,707.00
33,551.00
growth rate 5.2% 0.2% 6.1% 8.9% 7.5% -12.6% -5.9% 6.2% -0.5%
Cash 7,976.00
7,683.00
5,033.00
5,776.00
1,656.00
3,586.00
5,571.00
2,385.00
4,237.00
5,421.00
growth rate -3.7% -34.5% 14.8% -71.3% 116.6% 55.4% -57.2% 77.7% 27.9%
Inventory 1,765.00
1,413.00
1,204.00
1,384.00
1,657.00
1,498.00
1,560.00
1,221.00
1,241.00
1,166.00
growth rate -19.9% -14.8% 15.0% 19.7% -9.6% 4.1% -21.7% 1.6% -6.0%
Cur.Liabilities 6,710.00
6,313.00
6,739.00
7,780.00
8,279.00
12,440.00
8,461.00
8,017.00
8,841.00
9,563.00
growth rate -5.9% 6.8% 15.5% 6.4% 50.3% -32.0% -5.3% 10.3% 8.2%
Liabilities 17,245.00
16,165.00
15,363.00
17,014.00
22,274.00
23,438.00
18,766.00
17,324.00
17,360.00
21,704.00
growth rate -6.3% -5.0% 10.8% 30.9% 5.2% -19.9% -7.7% 0.2% 25.0%
LT Debt 4,380.00
6,585.00
6,130.00
5,328.00
5,376.00
6,568.00
7,981.00
7,245.00
6,558.00
5,716.00
6,975.00
growth rate 50.3% -6.9% -13.1% 0.9% 22.2% 21.5% -9.2% -9.5% -12.8% 22.0%
Equity 10,562.00
12,241.00
14,843.00
15,713.00
15,956.00
13,623.00
15,154.00
14,852.00
14,266.00
16,177.00
11,741.00
growth rate 15.9% 21.3% 5.9% 1.6% -14.6% 11.2% -2.0% -4.0% 13.4% -27.4%
Common Shares 1,980.00
1,999.00
1,974.00
1,727.00
1,717.00
1,688.00
1,662.00
1,670.00
1,679.00
1,680.00
1,652.00
growth rate 1.0% -1.3% -12.5% -0.6% -1.7% -1.5% 0.5% 0.5% 0.1% -1.7%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 843.00
-536.00
173.00
424.00
367.00
548.00
537.00
526.00
820.00
1,215.00
1,055.00
growth rate -100.0% 100.0% 145.1% -13.4% 49.3% -2.0% -2.1% 55.9% 48.2% -13.2%
Cash Dividends 2,213.00
2,461.00
2,483.00
2,202.00
2,254.00
2,286.00
2,309.00
2,398.00
2,477.00
2,547.00
2,577.00
growth rate 11.2% 0.9% -11.3% 2.4% 1.4% 1.0% 3.9% 3.3% 2.8% 1.2%
Cash From OA 3,153.00
3,707.00
4,065.00
4,491.00
4,840.00
6,941.00
3,545.00
3,148.00
2,105.00
3,058.00
5,275.00
growth rate 17.6% 9.7% 10.5% 7.8% 43.4% -48.9% -11.2% -33.1% 45.3% 72.5%
FCF per Share 1.17
1.38
1.68
2.37
2.64
3.79
1.48
2.07
0.64
0.54
2.54
growth rate 18.0% 21.7% 41.1% 11.4% 43.6% -61.0% 39.9% -69.1% -15.6% 370.4%
Sale Purchase of Stock -620.00
-1,940.00
131.00
288.00
-231.00
-231.00
-2,469.00
growth rate 0.0% 100.0% 119.9% -100.0% 0.0% 0.0%
FCF 2,310.00
2,766.00
3,335.00
4,067.00
4,473.00
6,393.00
3,008.00
2,622.00
1,012.00
1,635.00
4,220.00
growth rate 19.7% 20.6% 22.0% 10.0% 42.9% -53.0% -12.8% -61.4% 61.6% 158.1%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 15,620.00
17,715.00
18,808.00
19,484.00
21,244.00
17,621.00
16,385.00
15,879.00
16,560.00
19,427.00
20,776.00
growth rate 13.4% 6.2% 3.6% 9.0% -17.1% -7.0% -3.1% 4.3% 17.3% 6.9%
Op.Income 4,776.00
5,303.00
5,978.00
3,709.00
1,960.00
2,563.00
3,468.00
3,867.00
5,186.00
5,350.00
growth rate 11.0% 12.7% -38.0% -47.2% 30.8% 35.3% 11.5% 34.1% 3.2%
IBT 4,776.00
5,602.00
6,071.00
6,981.00
2,340.00
2,891.00
2,381.00
2,077.00
5,915.00
5,131.00
growth rate 17.3% 8.4% 15.0% -66.5% 23.6% -17.6% -12.8% 184.8% -13.3%
Net Income 5,247.00
10,612.00
3,102.00
3,709.00
1,960.00
2,563.00
2,004.00
1,565.00
4,457.00
1,007.00
growth rate 102.3% -70.8% 19.6% -47.2% 30.8% -21.8% -21.9% 184.8% -77.4%
EPS 1.09
2.62
5.34
1.79
2.16
1.16
1.54
1.20
0.93
2.65
0.61
growth rate 140.4% 103.8% -66.5% 20.7% -46.3% 32.8% -22.1% -22.5% 185.0% -77.0%
Gross Profit 10,698.00
12,399.00
13,668.00
14,207.00
15,646.00
13,011.00
11,766.00
12,098.00
12,735.00
14,502.00
14,859.00
growth rate 15.9% 10.2% 3.9% 10.1% -16.8% -9.6% 2.8% 5.3% 13.9% 2.5%
R&D 3,512.00
3,647.00
3,566.00
3,839.00
3,904.00
3,731.00
3,913.00
4,037.00
4,405.00
4,823.00
growth rate 3.8% -2.2% 7.7% 1.7% -4.4% 4.9% 3.2% 9.1% 9.5%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 1,367.00
1,103.00
1,473.00
1,621.00
1,690.00
growth rate -19.3% 33.5% 10.1% 4.3%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 5,588.00
5,609.00
5,358.00
5,636.00
5,884.00
growth rate 0.4% -4.5% 5.2% 4.4%
Acct.Payable 1,699.00
2,248.00
1,725.00
1,873.00
1,773.00
growth rate 32.3% -23.3% 8.6% -5.3%
Cur.Assets 15,048.00
14,854.00
14,649.00
13,874.00
14,869.00
growth rate -1.3% -1.4% -5.3% 7.2%
Total Assets 33,977.00
33,551.00
33,083.00
32,641.00
33,734.00
growth rate -1.3% -1.4% -1.3% 3.4%
Cash 4,644.00
5,421.00
5,342.00
4,999.00
5,408.00
growth rate 16.7% -1.5% -6.4% 8.2%
Inventory 1,250.00
1,166.00
1,231.00
1,242.00
1,282.00
growth rate -6.7% 5.6% 0.9% 3.2%
Cur.Liabilities 9,438.00
9,563.00
9,624.00
9,878.00
9,694.00
growth rate 1.3% 0.6% 2.6% -1.9%
Liabilities 19,063.00
21,704.00
20,177.00
20,223.00
19,984.00
growth rate 13.9% -7.0% 0.2% -1.2%
LT Debt 6,982.00
6,975.00
5,775.00
5,671.00
5,687.00
growth rate -0.1% -17.2% -1.8% 0.3%
Equity 14,783.00
11,741.00
12,793.00
12,317.00
13,640.00
growth rate -20.6% 9.0% -3.7% 10.7%
Common Shares 221.00
221.00
221.00
221.00
221.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 262.00
254.00
239.00
198.00
224.00
growth rate -3.1% -5.9% -17.2% 13.1%
Cash Dividends 640.00
639.00
653.00
654.00
653.00
growth rate -0.2% 2.2% 0.2% -0.2%
Cash From OA 1,713.00
1,117.00
1,175.00
1,057.00
1,279.00
growth rate -34.8% 5.2% -10.0% 21.0%
Sale Purchase of Stock -220.00
-249.00
-167.00
growth rate 0.0% 0.0%
FCF 1,451.00
863.00
936.00
859.00
1,055.00
growth rate -40.5% 8.5% -8.2% 22.8%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 5,254.00
5,449.00
5,193.00
5,704.00
5,691.00
growth rate 3.7% -4.7% 9.8% -0.2%
Op.Income 1,367.00
1,103.00
1,473.00
1,621.00
1,690.00
growth rate -19.3% 33.5% 10.1% 4.3%
IBT 1,183.00
698.00
1,779.00
517.00
2,167.00
growth rate -41.0% 154.9% -70.9% 319.2%
Net Income 845.00
-2,328.00
1,486.00
373.00
1,901.00
growth rate -100.0% 100.0% -74.9% 409.7%
EPS
growth rate
Gross Profit 3,683.00
3,794.00
3,622.00
4,093.00
4,055.00
growth rate 3.0% -4.5% 13.0% -0.9%
R&D 1,169.00
1,393.00
1,170.00
1,341.00
1,262.00
growth rate 19.2% -16.0% 14.6% -5.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (11.19)

YOY Growth Grade:

D (33.73)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 57.41 57.03 12.14
EPS / Growth 12.9% 0.87 12.3%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 8.7% 8.7%
Future PE 2.00 14.78 14.78
Future EPS 0.96 2.01 2.01
Value Price
MOS %
0.48
-99.0%
7.35
-85.2%
7.35
-85.2%
MOS Price 0.24 3.68 3.68
IRT 44.99 20.55 20.55

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.